FDA's draft early-phase IND guidance for solid tumours: what sponsors should do before 11 January

What happened

On 10 November 2026 the FDA issued a draft guidance on early-phase IND protocols for solid tumours. The Oncology Center of Excellence (OCE) wrote it, although the record we reviewed is filed under FDA CBER. The draft covers first-in-human trials and products with limited human experience. Comments are open until 11 January 2027, a window of roughly two months.

The guidance's URL slug calls it "early-phase IND protocol recommendations for solid tumors". The records give us the scope and the deadline, but not the detail of the recommendations. We have not seen the text on dose escalation, cohort design, expansion cohorts, monitoring or eligibility, so this article does not characterise them. Teams should read the document itself before drawing conclusions.

Why it matters

Early-phase protocols are where a development programme's later options are set. Choices about starting dose, escalation rules, safety monitoring and the patients enrolled determine what data a sponsor holds when it goes back to the agency. A draft aimed specifically at first-in-human work, and at products with little human exposure, signals that the OCE wants to set out its expectations for the earliest stage of oncology development.

The focus on "limited human experience" also matters. Novel modalities and first-of-a-kind constructs are the products where sponsors have the least precedent to lean on. Written FDA recommendations can reduce guesswork in IND submissions and in pre-IND discussions.

Regulatory context

A draft guidance is not binding. It represents the FDA's current thinking only once finalised, and the agency invites public comment first. The comment period is the one point at which sponsors, academic centres and trade groups can ask for clarifications or flag practical problems before the text settles. After comments close, the FDA may revise the draft. The records do not say when a final version might appear.

The wider context shows how early design choices feed into later regulatory dialogue. Zentalis Pharmaceuticals reported Q3 2026 results on 9 November and said it plans to seek FDA talks on accelerated approval for azenosertib after the DENALI readout in the first half of 2027. It said Part 2c enrolment completes in November and that its cash runway extends into the first half of 2028. The records do not link that programme to the new draft, and we do not suggest it is affected. It simply illustrates the sequence sponsors work through: trial design, enrolment, data readout, then agency discussions on a pathway, all within a funded timeline.

On the inspection side, the MHRA updated its guidance page on GCP inspections for clinical trials of medicines on 6 November 2026. The page describes risk-based and triggered inspections, dossier requests and the inspection process, and names ICH E6(R3) as the reference standard. The FDA draft addresses protocol content and the MHRA page addresses oversight of trial conduct, so they are different instruments. Sponsors running multi-region programmes will still need protocols that are defensible on design and conduct that meets inspection expectations.

Who is affected

The most direct audience is sponsors planning or running first-in-human solid-tumour trials under a US IND. That includes small biotechs, where one early protocol can define the programme, and academic sponsors. Clinical operations teams, medical monitors, biostatisticians and regulatory affairs staff all have a stake, because protocol language affects site workload, data collection and safety reporting.

Sponsors with products that have limited human experience should read the draft with their own development plans in front of them. Contract research organisations that write and operationalise early-phase protocols will also want to check their templates against the draft once they have read it.

What to watch

First, the comment docket. Submissions from industry and academic bodies will show which recommendations are contested. Second, whether the final guidance changes after 11 January 2027. Third, how the draft sits alongside existing FDA oncology guidance. The records do not address that, so teams should map any overlaps or conflicts themselves.

Finally, watch how inspection regimes treat early-phase trial conduct. The MHRA's reference to ICH E6(R3) is a reminder that design and conduct are assessed separately, and that a well-designed protocol does not make up for weak execution.